Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351831 | 1.00 | HSD11B1 (0.52) | HSD11B1CYP2D6PDK2ALDH1A1CHRM5 | |
| SCHEMBL351225 | 1.00 | HSD11B1 (0.52) | HSD11B1CYP2D6PDK2ALDH1A1CHRM5 | |
| SCHEMBL351224 | 1.00 | HSD11B1 (0.52) | HSD11B1CYP2D6PDK2ALDH1A1CHRM5 | |
| SCHEMBL351462 | 0.95 | HSD11B1 (0.54) | HSD11B1CYP2D6PDK2ALDH1A1 | |
| SCHEMBL350283 | 0.95 | HSD11B1 (0.54) | HSD11B1CYP2D6PDK2ALDH1A1 | |
| SCHEMBL350284 | 0.95 | HSD11B1 (0.54) | HSD11B1CYP2D6PDK2ALDH1A1 | |
| SCHEMBL351461 | 0.95 | HSD11B1 (0.54) | HSD11B1CYP2D6PDK2ALDH1A1 | |
| SCHEMBL16872697 | 0.91 | HSD11B1 (0.50) | HSD11B1CYP2D6 | |
| SCHEMBL350379 | 0.90 | HSD11B1 (0.49) | HSD11B1CYP2D6PDK2CHRM5 | |
| SCHEMBL349834 | 0.90 | HSD11B1 (0.55) | HSD11B1CYP2D6PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION | 2015-11-19 | — | — | US | claimed |
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | claimed |
| EP-1756063-B1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2015-07-08 | — | — | EP | claimed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | claimed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | claimed |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2007-08-02 | — | — | US | claimed |
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-22 | — | — | US | claimed |
| EP-2963021-A1 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Holdings Corporation (US) | 2016-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282858-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885PDK2 988/4885 |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885PDK2 988/4885 |
| US-20150329561-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885PDK2 988/4885 |
| US-20070179142-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HSD11B1 1/4885CYP2D6 358/4885PDK2 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.